The new generation spacer helps provide optimal protection to the rectum during prostate cancer radiation therapy. Credit: MattL_Images / Shutterstock.com.

Israel-based medical device company BioProtect has secured approval from the US Food and Drug Administration (FDA) for its new biodegradable balloon.

Named BioProtect Balloon ImplantSystem, the new generation spacer has been developed to offer consistent, reproducible and optimal protection to the rectum during radiation therapy for prostate cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is an implantable balloon that offers a specific enclosed distance to reduce radiation exposure to the rectum while undergoing therapy.

Designed to provide reproducible separation between the prostate and rectum, the spacer can be viewed under all imaging modalities, such as ultrasound, magnetic resonance imaging and computerised tomography.

Utilising a blunted tip insertion device, the biodegradable spacer can be deployed through a rapid and minimally invasive procedure.

BioProtect CEO Itay Barnea said: “We believe that our balloon has the potential to revolutionise rectal protection from toxicity during prostate cancer radiation therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Not only does it provide better protection to healthy organs, it also supports dose escalation and hypofractionation, which are leading trends in prostate cancer radiation therapy.”

As per the American Cancer Society, prostate cancer is the second-most prevalent cancer among men in the US, with 288,300 newly diagnosed cases this year.

The company has appointed Ken Knudson as general manager and chief commercial officer to advance its penetration into the US market.

The BioProtect Balloon spacer is already commercialised in Europe and is supported by the Consensus Business Group of Vincent Tchenguiz, Peregrine Ventures, KB Investment, Almeda Ventures and Triventures.